Background Lobectomy is the standard of care for early-stage non-small-cell lung cancer (NSCLC).
The survival and clinical benefits of segmentectomy have not been investigated in a …

Since ‘radical lobectomy’ was reported by Cahan in 1960, the standard surgical care for
lung cancer has been lobectomy, in which units of the lobe are excised with their specific …

The balance of programmed death-1 (PD-1)-expressing CD8 + T cells and regulatory T (Treg)
cells in the tumor microenvironment (TME) determines the clinical efficacy of PD-1 …

Immune checkpoint blockade has provided a paradigm shift in cancer therapy, but the success
of this approach is very variable; therefore, biomarkers predictive of clinical efficacy are …

The treatments for advanced non-small cell lung cancer (NSCLC) should control both local
and microscopic systemic disease, because the 5-year survival of patients with Stage III …

BACKGROUND. The purpose of this study was to investigate whether tumor‐infiltrating
immune cells in biopsy specimens can be used to predict the clinical outcome of stage IV …

Progress in genetic engineering has made it possible to elucidate the molecular biological
abnormalities in lung cancer. Mutations in KRAS and P53 genes, loss of specific alleles, and …

Background No definitive comparisons of surgical morbidity between segmentectomy and
lobectomy for non–small cell lung cancer have been reported. Methods We conducted a …

Background The optimal mode of surgery for ground-glass opacity dominant peripheral lung
cancer defined with thoracic thin-section computed tomography remains unknown. Methods …

PD-1 blockade exerts antitumor effects by reinvigorating tumor antigen–specific CD8 + T cells.
Whereas neoantigens arising from gene alterations in cancer cells comprise critical tumor …